Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone in TSC-Related Epilepsy (TrustTSC)
NCT05323734Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Allosteric Modulators
- Countries
- 10
01
Overview
A Phase 3 trial of ganaxolone in tuberous sclerosis complex (TSC), epilepsy, sponsored by Marinus Pharmaceuticals. Started Apr 2022; status: completed.
02
Drugs
ganaxolone
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on NCT05323734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323734.